Information Provided By:
Fly News Breaks for February 5, 2016
BMY
Feb 5, 2016 | 07:37 EDT
JPMorgan analyst Chris Schott sees an attractive opportunity for shares of Bristol-Myers following the recent pullback. He reiterates an Overweight rating on the name with an $80 price target. The analyst sees a number of Immuno-Oncology catalysts for shares of Bristol over the next 12-18 months.